Will US FDA Offer Regulatory Flexibility For ANDAs Downgraded Because Of CRO Investigation?

 
• By Derrick Gingery
  
Two doors, two choices
The FDA is offering most sponsors two doors, redoing the BE studies or withdrawing the application, but each has its own challenges. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics